Cargando…
Clinical Distribution Characteristics of 1439 Carbapenem-Resistant Escherichia coli Strains in China: Drug Resistance, Geographical Distribution, Antibiotic MIC50/90
PURPOSE: To explore the clinical distribution characteristics and antimicrobial susceptibilities of carbapenem-resistant Escherichia coli (CR-ECO) in Hebei Province, China, from 2017 to 2019, and provide data on the treatment of this bacterial infection and the prevention of its spread. MATERIALS AN...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8594617/ https://www.ncbi.nlm.nih.gov/pubmed/34795488 http://dx.doi.org/10.2147/IDR.S334283 |
_version_ | 1784600022771302400 |
---|---|
author | Zhang, Wei Li, Zhirong Wang, Na Yang, Zhicong Li, Jia Li, Caiqing Han, Xuying Liu, Jinlu Li, Liping Wang, Shuwang Zhan, Minghua |
author_facet | Zhang, Wei Li, Zhirong Wang, Na Yang, Zhicong Li, Jia Li, Caiqing Han, Xuying Liu, Jinlu Li, Liping Wang, Shuwang Zhan, Minghua |
author_sort | Zhang, Wei |
collection | PubMed |
description | PURPOSE: To explore the clinical distribution characteristics and antimicrobial susceptibilities of carbapenem-resistant Escherichia coli (CR-ECO) in Hebei Province, China, from 2017 to 2019, and provide data on the treatment of this bacterial infection and the prevention of its spread. MATERIALS AND METHODS: A total of 1439 CR-ECO strains were collected from 2017 to 2019 in Hebei Province, China. Drug sensitivity tests were performed using the minimum inhibitory concentration (MIC) method, and the data were analyzed statistically using WHONET5.6 software. RESULTS: A total of 54,377 strains of Escherichia coli were isolated in Hebei Province from 2017 to 2019, of which 1439 strains were CR-ECO (2.65%). The highest proportion (33.78%) of strains was isolated from urine, and the detection rate showed a slow downward trend over the past 3 years. CR-ECO was mainly detected in densely populated and economically developed areas. Of all the patients, 54.2% were from the medical ward; the ratio of male to female patients with CR-ECO infections was 1.35:1; elderly patients and adults accounted for 59.6% and 30.8%, respectively, whereas minors and newborns accounted for 4.9% and 4.7%, respectively. For CR-ECO, the drug resistance rates to β-lactams were all higher than 80% and there was an annual increasing trend, while the drug resistance rates to quinolones remained nearly unchanged. The rate of resistance to aminoglycosides was relatively low, especially to amikacin (approximately 22%). The MIC50 of other antibacterial drugs, except amikacin, was equal to or higher than the break point of drug resistance. CONCLUSION: From 2017 to 2019, the isolation rate of CR-ECO in Hebei Province, China, remained stable; however, the drug resistance rate showed an upward trend, primarily in cases of urinary tract infections in older men; the resistance rate to amikacin was the lowest. |
format | Online Article Text |
id | pubmed-8594617 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-85946172021-11-17 Clinical Distribution Characteristics of 1439 Carbapenem-Resistant Escherichia coli Strains in China: Drug Resistance, Geographical Distribution, Antibiotic MIC50/90 Zhang, Wei Li, Zhirong Wang, Na Yang, Zhicong Li, Jia Li, Caiqing Han, Xuying Liu, Jinlu Li, Liping Wang, Shuwang Zhan, Minghua Infect Drug Resist Original Research PURPOSE: To explore the clinical distribution characteristics and antimicrobial susceptibilities of carbapenem-resistant Escherichia coli (CR-ECO) in Hebei Province, China, from 2017 to 2019, and provide data on the treatment of this bacterial infection and the prevention of its spread. MATERIALS AND METHODS: A total of 1439 CR-ECO strains were collected from 2017 to 2019 in Hebei Province, China. Drug sensitivity tests were performed using the minimum inhibitory concentration (MIC) method, and the data were analyzed statistically using WHONET5.6 software. RESULTS: A total of 54,377 strains of Escherichia coli were isolated in Hebei Province from 2017 to 2019, of which 1439 strains were CR-ECO (2.65%). The highest proportion (33.78%) of strains was isolated from urine, and the detection rate showed a slow downward trend over the past 3 years. CR-ECO was mainly detected in densely populated and economically developed areas. Of all the patients, 54.2% were from the medical ward; the ratio of male to female patients with CR-ECO infections was 1.35:1; elderly patients and adults accounted for 59.6% and 30.8%, respectively, whereas minors and newborns accounted for 4.9% and 4.7%, respectively. For CR-ECO, the drug resistance rates to β-lactams were all higher than 80% and there was an annual increasing trend, while the drug resistance rates to quinolones remained nearly unchanged. The rate of resistance to aminoglycosides was relatively low, especially to amikacin (approximately 22%). The MIC50 of other antibacterial drugs, except amikacin, was equal to or higher than the break point of drug resistance. CONCLUSION: From 2017 to 2019, the isolation rate of CR-ECO in Hebei Province, China, remained stable; however, the drug resistance rate showed an upward trend, primarily in cases of urinary tract infections in older men; the resistance rate to amikacin was the lowest. Dove 2021-11-12 /pmc/articles/PMC8594617/ /pubmed/34795488 http://dx.doi.org/10.2147/IDR.S334283 Text en © 2021 Zhang et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Zhang, Wei Li, Zhirong Wang, Na Yang, Zhicong Li, Jia Li, Caiqing Han, Xuying Liu, Jinlu Li, Liping Wang, Shuwang Zhan, Minghua Clinical Distribution Characteristics of 1439 Carbapenem-Resistant Escherichia coli Strains in China: Drug Resistance, Geographical Distribution, Antibiotic MIC50/90 |
title | Clinical Distribution Characteristics of 1439 Carbapenem-Resistant Escherichia coli Strains in China: Drug Resistance, Geographical Distribution, Antibiotic MIC50/90 |
title_full | Clinical Distribution Characteristics of 1439 Carbapenem-Resistant Escherichia coli Strains in China: Drug Resistance, Geographical Distribution, Antibiotic MIC50/90 |
title_fullStr | Clinical Distribution Characteristics of 1439 Carbapenem-Resistant Escherichia coli Strains in China: Drug Resistance, Geographical Distribution, Antibiotic MIC50/90 |
title_full_unstemmed | Clinical Distribution Characteristics of 1439 Carbapenem-Resistant Escherichia coli Strains in China: Drug Resistance, Geographical Distribution, Antibiotic MIC50/90 |
title_short | Clinical Distribution Characteristics of 1439 Carbapenem-Resistant Escherichia coli Strains in China: Drug Resistance, Geographical Distribution, Antibiotic MIC50/90 |
title_sort | clinical distribution characteristics of 1439 carbapenem-resistant escherichia coli strains in china: drug resistance, geographical distribution, antibiotic mic50/90 |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8594617/ https://www.ncbi.nlm.nih.gov/pubmed/34795488 http://dx.doi.org/10.2147/IDR.S334283 |
work_keys_str_mv | AT zhangwei clinicaldistributioncharacteristicsof1439carbapenemresistantescherichiacolistrainsinchinadrugresistancegeographicaldistributionantibioticmic5090 AT lizhirong clinicaldistributioncharacteristicsof1439carbapenemresistantescherichiacolistrainsinchinadrugresistancegeographicaldistributionantibioticmic5090 AT wangna clinicaldistributioncharacteristicsof1439carbapenemresistantescherichiacolistrainsinchinadrugresistancegeographicaldistributionantibioticmic5090 AT yangzhicong clinicaldistributioncharacteristicsof1439carbapenemresistantescherichiacolistrainsinchinadrugresistancegeographicaldistributionantibioticmic5090 AT lijia clinicaldistributioncharacteristicsof1439carbapenemresistantescherichiacolistrainsinchinadrugresistancegeographicaldistributionantibioticmic5090 AT licaiqing clinicaldistributioncharacteristicsof1439carbapenemresistantescherichiacolistrainsinchinadrugresistancegeographicaldistributionantibioticmic5090 AT hanxuying clinicaldistributioncharacteristicsof1439carbapenemresistantescherichiacolistrainsinchinadrugresistancegeographicaldistributionantibioticmic5090 AT liujinlu clinicaldistributioncharacteristicsof1439carbapenemresistantescherichiacolistrainsinchinadrugresistancegeographicaldistributionantibioticmic5090 AT liliping clinicaldistributioncharacteristicsof1439carbapenemresistantescherichiacolistrainsinchinadrugresistancegeographicaldistributionantibioticmic5090 AT wangshuwang clinicaldistributioncharacteristicsof1439carbapenemresistantescherichiacolistrainsinchinadrugresistancegeographicaldistributionantibioticmic5090 AT zhanminghua clinicaldistributioncharacteristicsof1439carbapenemresistantescherichiacolistrainsinchinadrugresistancegeographicaldistributionantibioticmic5090 |